Vmbook Online ordering

Drug Delivery

Sure, here are some general information and data points for Acura Pharmaceory stock symbol ACUR,

Company overview:

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in research, development, and commercialization of technically-challenging generic drugs, as well as developing proprietary drugs utilizing its implant technology. Its main focus is on the pain management and CNS (central nervous system) therapeutic areas. The company was founded in 2003 and is headquartered in Palatine, Illinois.

Stock Information:

ACUR is publicly traded on the OTCQB (Over-the-counter quotation board) marketplace, a middle-tier over-the-counter (OTC) market for American equities run by OTC Markets Group.

Financial Performance:

In the last quarter, Acura Pharmaceuticals' revenue was $21.1 million, a 16% rise year over year. Analysts anticipate its full-year revenue will increase 20% to $87.67 million in 2022, up from $72.54 million in 2021. The business reported a net loss of $4.9 million, as opposed to $2.9 million a year earlier. The 14.7% sequential increase in R&D expenses to $2.7 million negatively impacted the company's bottom line.

Earnings:

Acura Pharmaceuticals has yet to report its next earnings date. Its next earnings release is expected to be on August 15, 2023.

Growth:

Analysts anticipate Acura Pharmaceutical's earnings to grow 24% annually for the next five years. The company's long-term projected EPS growth rate is 12%.

Insider Activity:

There has been quite a bit of insider trading activity. Over the past year, insiders purchased 1.42 million shares of ACUR stock. There have been no instances of insider selling during that period. This can be a sign that insiders are confident in the company's prospects.

Divident:

ACUR does not pay a dividend.

Price Performance:

Over the past year, the stock price of ACUR has fallen by about 3.5%, significantly underperforming the industry's 2.8% gain. Its price declined even further in the last month, dropping 15.5%. It is rated a #4 (Sell) stock and has a C-rating for sentiment.

Analyst's take:

Zacks Investment Research cut Acura Pharmaceuticals from a "buy" rating to a "Sell" rating in a report issued on April 6, 2022.

Conclusion:

This information should provide you with a fair understanding of ACUR's business and financial performance. However, it's essential to note that investing in the stock market carries risks, and various factors can influence stock performance. To make wise investment decisions, it is always advisable to do comprehensive research and consult with financial advisors.